MiNK Therapeutics, Inc 8-K, filed Jun 18, 2025
MiNK Therapeutics, Inc. (INKT)
About this 8-K
MiNK Therapeutics, Inc filed this 8-K on June 18, 2025.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 18, 2025. A total of 2,793,022 shares of common stock, representing 70.41% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 30, 2025: (i) to elect Jennifer Buell and Ulf Wiinberg as Class I directors, each for a term of three years expiring at the 2028 Annual Meeting of Stockholders (“Proposal 1”), (ii) to approve the option exchange proposal (“Proposal 2”), and (iii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (“Proposal 3”).
The Company’s stockholders elected each of the Class I director nominees nominated for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class I directors as follows:
Class I Director Nominees |
For |
Against |
Withheld |
Broker Non-Votes |
Jennifer Buell |
2,337,073 |
0 |
31,146 |
424,803 |
Ulf Wiinberg |
2,312,077 |
0 |
56,142 |
424,803 |
The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:
For |
Against |
Abstain |
Broker Non-Votes |
2,269,364 |
97,538 |
1,317 |
424,803 |
The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:
For |
Against |
Abstain |
Broker Non-Votes |
2,773,188 |
12,846 |
6,988 |
0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
Date: |
June 18, 2025 |
By: |
/s/ Jennifer S. Buell, Ph.D. |
|
|
|
Jennifer S. Buell, Ph.D. |